Slingshot members are tracking this event:
OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|OPK||Community voting in process|
Currently, Factor VIIa therapy is available only as an intravenous (IV) formulation which, due to Factor VIIa's short half-life, requires multiple infusions to treat a bleeding episode in hemophilia A or B patients with inhibitors. In addition, frequent infusions are onerous when used as prophylactic therapy, especially for children. Pre-clinical studies of intravenous and subcutaneous formulations of our product in hemophilic animal models demonstrated its duration of action and significantly increased survival.
Slingshot Insights Explained
Feb 23, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2a, Clinical Study, Hemophilia, Hemophilia A, Hemophilia B